There are many international guidelines that have been developed to ensure that the conduct of researches by countries, institutions and individuals are ethical. There are, however, unique opportunities as well as challenges in research in the ASEAN region which mandate not only adherence to these guidelines but which necessitate regional as well as individual country efforts to ensure that biomedical researches uphold the dignity, ensure safety and protect the rights of participants. Some of the challenges are: the widespread poverty or uneven distribution of resources in developing countries which cause patients to participate in clinical trials to avail of services that otherwise are inaccessible, lack of a research infrastructure that makes ethics review of protocols inadequate or slow, and lack of post-trial access to medications which have been tested in precisely the populations that need these drugs. The aim of this paper is to review the ethical challenges in health research encountered in Asia and to describe the regional efforts being undertaken to address them.
Introduction
Many international guidelines on research ethics have been developed to guide countries and institutions on the proper conduct of biomedical research and to protect the dignity, safety and rights of human research participants. The most frequently mentioned is the Declaration of Helsinki by the World Medical Association (WMA), with its latest revision in 2008. 1 Practice (1996) , both of which set the standards for the conduct of clinical trials. [2] [3] [4] On the other hand, the United Nations Educational, Scientific and Cultural Organization (UNESCO) adopted the Universal Declaration on Bioethics and Human Rights in 2005 to assist member states in the formulation of national legislation, regulations and policies. 5 The report by the Nuffield Council on Bioethics, The Ethics of Research Related to Healthcare in Developing Countries (2002, followed up in 2005) , is also frequently referred to by researchers and ethics review committees in many countries. 6 Recently the World Health Organization released a new set of guidelines for ethical review of research, Ethics Review
Standards and Operational Guidance for Ethics Review of Health-Related Research with Human Participants. World Health Organization 2011.
In light of the many developments in health research (e.g., genomics, biobanking, drug and vaccine development, and discovery of natural products) and the current globalization of biomedical research activities, it is important to appreciate the efforts being made for protection of human participants in research in our region. 7 The aim of this paper is to review the ethical challenges in health research encountered in Asia and to describe the regional efforts to address them. The Philippine human protection system is presented as a specific example of a national initiative towards ethical health research. Most of the perceptions and opinions expressed in the article are results of the author's participation in some of the activities of the Forum for Ethical Review Committees in Asia and the Western Pacific Region (FERCAP), and her involvement as chair of the National Ethics Committee and co-chair of the Philippine Health Research Ethics Board in the past years.
Issues and challenges
The Helsinki Declaration and the other aforementioned international guidelines expressly require that all biomedical researches involving human participants Speakers in various fora have noted a large variation in the abilities of developing countries to carry out an effective and adequate ethical review of health researches. [8] [9] [10] Reasons often cited are:
1. Non-existent health data systems 2. Difficulty in recruiting qualified committee members 3. Lack of ethics review training programs 4. Absence of a quality assurance system in ethical review 5. Administrative support is lacking These deficiencies result in delays in the review process, post-review communications and inconsistency in ethical review decisions. These subsequently cause delay in the implementation of the study, loss of credibility of the ethics review committee and diminution of support in the ethics review process.
For example, to ensure that a study is not exploitative of the community, the ethics review committee will assess whether the research addresses a significant national or local health problem. Evidence to support relevance is usually in the form of reliable epidemiologic data. Unfortunately these data are not always available. Corollary to the issue of relevance is the community's post-study accessibility to the treatment that is proven effective. Pharmaceutical companies hedge the question of cost (as a determinant of accessibility) of a drug or vaccine by explaining that the cost can only be determined by the size of the market and the overall investment in its development. These can only be computed after all the required trials for drug registration are done. This reasoning is a nudge to the ethics committee to approve the drug trial so that the clinical trials can be done and all the marketing factors can be quickly determined.
Pervasive poverty in many Asian countries and the absence of universal health care programs bring about lack of access to medical treatment. This creates a situation in which clinical trials become the default means whereby patients get attention and care. Therapeutic misconception and the inability of the participants to distinguish research from clinical treatment make the informed consent process difficult to acquire.
Teck-Chuan Voo et al highlighted the issue of access to standard care by patients participating in medical studies based on the Declaration of Helsinki, which stipulated that in "every medical study, every patient-including those of a control group, if any-should be assured of the best proven diagnostic and therapeutic method." 11 The authors considered whether "the provision of care for control groups adhere to a universal standard-the best current treatment worldwide, or at least an established and effective intervention? Should it be the local de facto standard-the actual health care practices of the host country? Or should it perhaps adhere to the local de jure standard, reflecting the judgments of medical experts in the host community on the most effective treatment and care practices for that community?" When international guidelines are not clear, the local ethics review committee will be very much dependent on a consensus of its inexperienced members.
A fundamental principle of research ethics is that the consent of the potential research participant must be voluntary and shall be based on sufficient knowledge and understanding of the procedures, risks and benefits involved.
Conceptually difficult topics like genetics/genomics and the necessary translation of complex research procedures in the local language present challenges in the informed consent process. Frequently, the literal translation of the informed consent form into a dialect fails to capture the nuances of scientific jargon and those of a foreign language. Additionally, there are social and cultural norms-like permission from the spouse (usually the male), family or community-which are traditionally sought in many Asian countries, that are not sufficiently considered in the international guidelines.
Initiatives in Research Ethics in Asia

Regional and international conferences
In the past decade, Asia has hosted many international and regional conferences that have provided opportunities to raise awareness on the ethical challenges in health researches in the region. The following are some examples of these conferences. 
Other initiatives
Regional and individual country strategies that address the ethical challenges in health researches in Asia have been varied. These include the conduct of regional conferences, development of regional and national research ethics training courses (masters courses and intensive courses in both campus-based and distance learning modes), establishment of quality assurance systems, development of national GCP guidelines and the establishment of health research databases. 12 
Summary of country initiatives in research ethics
In On the other hand, the Philippines has developed specific guidelines for researches in organ transplantation, genetic engineering, HIV/AIDS, and assisted reproductive technology. Other countries like Malaysia and Singapore have developed their own version of GCP to guide ethical review. These national guidelines generally followed the major international research ethics guidelines. She noted that in some parts of Asia, community involvement in assessing research ethics review structures is becoming increasingly common. Community involvement often stems from community initiatives to become active participants. In Thailand, for example, an HIV study group has created a community advisory board that liaise with the host community to deal with research ethics review issues. 15 Countries like Indonesia, Malaysia, Cambodia, Vietnam, Laos and the Philippines have established national ethics committees that review biomedical researches. Dr. Torres pointed out that as with many other jurisdictions, the problem of enforcement remains. Research ethics guidelines do not have legal authority, only moral force.
Philippine initiatives in health research ethics
In 1984, the Philippine Council for Health Research and Development under the Department of Science and Technology (DOST) created the National Ethics Committee (NEC), which was tasked to ensure that health researches in the Philippines adhered to international ethical guidelines. The following year, the committee formulated the National Guidelines for Biomedical Research. The latest edition, the 2011 National Ethical Guidelines for Health Research, was released on 16 March 2012. 16 On March 17, 2003, key agencies of government-the DOST, the Department of Health (DOH), the Commission on Higher Education (CHED), and subsequently the University of the Philippines Manila -National Institutes of Health (UPM-NIH)-signed a memorandum of understanding that established the Philippine National Health Research System (PNHRS). The PNHRS shall promote and enhance cooperation and sharing of resources, and the development of the capacity for knowledge production, use, management, research and financing.
The PNHRS envisions a vibrant, dynamic and responsible health research community for the attainment of national and global health goals. One of its strategic goals is the development of high-performing and ethical research organizations. To see to the attainment of this goal, the Philippine Health Research Ethics Board (PHREB) was created through DOST Special Order 091 s. 2006 as the national policy-making body on health research. The PHREB shall formulate guidelines for ethical conduct in health research, and establish and manage ethics review committees (ERCs). It was also mandated to monitor the performance of ERCs, and to provide advice to the PNHRS Governing Council and to other appropriate entities (including the Food and Drug Administration) related to ethical issues in human health research.
Structurally, the PHREB became one of the 3 regulatory bodies on human protection in research; the others being the Food and Drug Administration and research institutions themselves (Figure 1) . The second level of control in human protection lies on the researcher, the sponsor and the ethics review committee. At the center, representing the first level of protection, is the research participant/patient.
In the past 5 years, the PHREB accomplished several important actions that made an impact health research ethics. Among these are: Some recent national policies regarding research are presented in Table 2 . 
Conclusion
Capacity-building in health research ethics is robust in Asia. There are international, regional and national efforts to respond to the challenge of ensuring that health research is conceptualized and conducted in a manner that is protective of the dignity and respectful of the rights of human participants.
